This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR"). Arecor Therapeutics plc(“Arecor” or the “Company”) Co-development Agreement with US Insulin Pump Device Company for AT278 andSale of Royalty and Technology Access Fees for up to $11 million AT278 (500U/mL) is the only ultra-concentrated and ultra-rapid acting insulin in development designed to enable the next generation of longer-wear and miniaturised autom ...